Discussing the Early Phase 1 Data of AstraZeneca's ESO-T01 (In Vivo Anti-BCMA CAR-T Therapy) for Relapsed/Refractory Multiple Myeloma

Executed on:Apr 21, 2026 3:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Dana-Farber Cancer Institute and Harvard Medical SchoolProgram Director of the Jerome Lipper Multiple Myeloma Center; Kraft Family Professor of Medicine at Harvard Medical School
Manages 500 patients per year with multiple myeloma, and 40-50 per year of those are treated with CAR-T
Pioneered multiple myeloma research and therapeutics, with seminal contributions to the development of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and combination regimens that have transformed myeloma care. Leads and collaborates on landmark clinical trials and translational research focused on tumor microenvironment, drug resistance, and immune-based therapies; has authored 1,000+ peer-reviewed publications and plays a central role in international guidelines, advisory boards, and scientific leadership shaping the future of myeloma treatment

Interview Goal

To gain a deeper understanding of ESO-T01 (In Vivo Anti-BCMA CAR-T Therapy) as a potential treatment for Relapsed/Refractory Multiple Myeloma

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.